|
Press Releases |
|
 |
|
Friday, March 21, 2025 |
|
China Medical System (00867) Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum |
On March 17, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease of 6.8%; in the case that all medicines were directly sold by the Company, the turnover would be RMB8,622 million, representing a year-on-year decrease of 9.0%. more info >> |
|
Friday, February 14, 2025 |
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025 |
In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ("CMS" or the "Group") has been included in the S&P Global Sustainability Yearbook 2025 (the "Yearbook 2025"). more info >> |
|
Friday, January 24, 2025 |
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 more info >> |
|
Thursday, January 9, 2025 |
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
Monday, December 9, 2024 |
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China |
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China more info >> |
|
Monday, December 2, 2024 |
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
Monday, October 21, 2024 |
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
Tuesday, September 24, 2024 |
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
Friday, August 16, 2024 |
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
Monday, August 5, 2024 |
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind
May 30, 2025 19:00 HKT/SGT
|
|
|
Mitsubishi Corporation Establishes New Corporate Venture Capital Company
May 30, 2025 18:36 JST
|
|
|
The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch
May 30, 2025 14:00 HKT/SGT
|
|
|
Honda to Co-develop Refueling Port Connecting System for On-orbit Satellite Refueling with Astroscale
May 30, 2025 11:54 JST
|
|
|
IFS and NEC Strengthen their Strategic Partnership to Create New Value
May 30, 2025 10:11 JST
|
|
|
Genetec maintains profitability in Q3FY2025 on higher revenue
May 29, 2025 20:00 HKT/SGT
|
|
|
Naoris Protocol Raises $3M in Strategic Round Led by Mason Labs
May 29, 2025 19:00 HKT/SGT
|
|
|
MODONG Coffee Proudly Sponsors "G-DRAGON 2025 WORLD TOUR [Ubermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" as Official Sponsor
May 29, 2025 18:19 HKT/SGT
|
|
|
Mazda Production and Sales Results for April 2025
May 29, 2025 18:44 JST
|
|
|
Euro Manganese Closes C$11.2 million (A$12.3 million) Financing
May 29, 2025 16:09 HKT/SGT
|
|
|
First patient dosed in YK012 trial-the world's first TCE therapy for primary membranous nephropathy
May 29, 2025 15:49 HKT/SGT
|
|
|
SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign "Life's too Short, You Gotta Chew" at THAIFEX - ANUGA ASIA 2025
May 29, 2025 08:00 HKT/SGT
|
|
|
Global Leaders Gather for XIII International Meeting on International Cooperation
May 28, 2025 20:30 HKT/SGT
|
|
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025 19:57 HKT/SGT
|
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28, 2025 17:45 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|